Abstract: The present invention provides a method for treating an ocular disease such as age-related macular degeneration (AMD), diabetic retinopathy (DR) or macular edema (ME), which comprises administering to a subject in need thereof a composition comprising a therapeutically effective amount of beauvericin.

Abstract: The present invention provides a method for treating an ocular disease such as age-related macular degeneration (AMD), diabetic retinopathy (DR) or macular edema (ME), which comprises administering to a subject in need thereof a composition comprising a therapeutically effective amount of beauvericin.

Abstract: The present invention is related to a method for wound healing comprising administering to a subject in need thereof a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound having the general Formula I, preferably salsolinol.

Abstract: The present invention provides a method for activating the AMP-dependent protein kinase (AMPK) in a subject comprising administering the subject with a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound having the general Formula I, preferably salsolinol or reticuline. The pharmaceutical composition is able to activate AMPK, and thus is effective in the regulation of cell growth and metabolism, and the treatment of AMPK associated diseases.

Abstract: The present invention is related to a method for diabetic wound healing comprising administering to a subject in need thereof a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound having the general Formula I, preferably salsolinol.

Abstract: The present invention provides a method for activating the AMP-dependent protein kinase (AMPK) in a subject comprising administering the subject with a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound having the general Formula I, preferably 1,10-dihydroxyaporphine. The pharmaceutical composition is able to activate AMPK, and thus is effective in the regulation of cell growth and metabolism, and the treatment of AMPK associated diseases.

Abstract: The present invention provides a method for activating the AMP-dependent protein kinase (AMPK) in a subject comprising administering the subject with a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound having the general Formula I, preferably 1,10-dihydroxyaporphine. The pharmaceutical composition is able to activate AMPK, and thus is effective in the regulation of cell growth and metabolism, and the treatment of AMPK associated diseases.

Abstract: The present invention provides a method for activating the AMP-dependent protein kinase (AMPK) in a subject comprising administering the subject with a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound having the general Formula I, preferably salsolinol or reticuline. The pharmaceutical composition is able to activate AMPK, and thus is effective in the regulation of cell growth and metabolism, and the treatment of AMPK associated diseases.

Abstract: A compound for controlling blood glucose level has a structure shown in Formula I: wherein R5-R8 are as defined herein. A method for controlling blood glucose level includes administering to a subject in need thereof a compound of Formula I. The method further includes administering to the subject a GLP-1 receptor ligand. The compound and the GLP-1 receptor ligand may be administered together. The compound may be Galanal A or Galanal B. The GLP-1 receptor ligand may be GLP-1 or exendin-4.

Abstract: The present invention is directed to therapeutic methods and compositions for treating insulin resistant diabetes or diabetes with inflammation in a subject comprising administering an effective amount of borapetoside A, or a pharmaceutically acceptable salt, metabolite, solvate or prodrug thereof, to said subject.

Abstract: The present invention is directed to therapeutic methods and compositions for treating type 1 diabetes in a subject comprising administering an effective amount of borapetoside A or C, or a pharmaceutically acceptable salt, metabolite, solvate or prodrug thereof, and insulin to said subject.

Abstract: The present invention relates to a plant extract for treating diabetes and a process for making same. The plant extract of the invention is prepared from an overground part of Hedychium coronarium Koenig, which has the efficacies of lowering blood glucose, increasing insulin levels, reducing insulin resistance and treating and/or preventing diabetes without overly reducing blood glucose in a subject, i.e., not reducing blood glucose in a fasting subject. Also provided herein is a method for treating diabetes in a subject in need thereof comprising administering an effective amount of the plant extract to the subject.

Abstract: A compound for controlling blood glucose level has a structure shown in Formula I: wherein R5-R8 are as defined herein. A method for controlling blood glucose level includes administering to a subject in need thereof a compound of Formula I. The method further includes administering to the subject a GLP-1 receptor ligand. The compound and the GLP-1 receptor ligand may be administered together. The compound may be Galanal A or Galanal B. The GLP-1 receptor ligand may be GLP-1 or exendin-4.

Abstract: The present invention relates to a plant extract for treating diabetes and a process for making same. The plant extract of the invention is prepared from an overground part of Hedychium coronarium Koenig, which has the efficacies of lowering blood glucose, increasing insulin levels, reducing insulin resistance and treating and/or preventing diabetes without overly reducing blood glucose in a subject, i.e., not reducing blood glucose in a fasting subject. Also provided herein is a method for treating diabetes in a subject in need thereof comprising administering an effective amount of the plant extract to the subject.

Abstract: The present invention relates to compounds of formual (I): wherein Y is a single bond or double bound; and R1 is —C(CH3)C2H5 or —C(CH3)?CHCH3, when Y is a single bound; R1 is —C(CH3)?CH2, is —C(CH3)2, —C(CH3)?CHCH3, —C(CH3)C2H5, or —CH2C(CH3)2, when Y is a double bound. These compounds are bombesin receptor subtype 3 (BRS3) modulating agents, more specifically that they are BRS3 agonists. The invention is also related to the use of such compounds to treat diseases associated with inappropriate BRS3 activity.

Abstract: A pharmaceutical composition for preventing and treating cancer comprising furost-5-ene-3,22,26-triol glycoside, which can be used to prevent and treat cancer by promoting apoptosis.

Abstract: A method for lowering the plasma glucose level in a subject and for treating diabetes with a diterpenoid compound.

Abstract: The present invention discloses thaliporphine and its derivatives for the treatment and/or prophylaxis of cardiac diseases, including cardiac arrhythmia, myocardial ischemia or myocardial infarction, and sudden death caused by cardiac arrhythmia or acute myocardial infarction.

Abstract: Novel secoaporphine compounds having the formula I ##STR1## wherein a) R.sub.1, R.sub.2 and R.sub.3, R.sub.4 are each methyl group; or b) R.sub.1, R.sub.2, and R.sub.4 are each methyl group; R.sub.3 is benzyl, ethyl or allyl; or c) R.sub.1, R.sub.2, and R.sub.3 are each hydrogen, R.sub.4 is methyl; or d) R.sub.1 and R.sub.2 are each hydrogen, R.sub.3 is benzyl, R.sub.4 is methyl; or e) R.sub.1 and R.sub.2 are each hydrogen, R.sub.3 is cyano, R.sub.4 is methyl group, and a salt thereof with a pharmaceutically acceptable acid. The novel compounds are useful in the treatment of arrhythmia.